Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop shows promise for glaucoma patients in large trial

NCT ID NCT07082816

Disease control Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new eye drop called Reformulated PG324 to see how well it lowers eye pressure in people with open-angle glaucoma or high eye pressure. About 489 adults took part. The goal was to measure the drop's safety and effectiveness in controlling eye pressure, which is key to managing these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

489 people

The number who actually took part.

Started

Sep 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in both eyes; * Unmedicated intraocular pressure measurements in the study eye as specified in the protocol; * Corrected distance visual acuity equal to or better than 20/100 in the study eye. Key Exclusion Criteria: * Current use of more than 2 ocular hypotensive medications within 30 days; * Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening; * Use of topical ocular medication of any kind within 5 days of Screening or throughout the study with the exception of ocular hypotensive medications (must be washed out).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ocular hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ocular hypertension Open angle glaucoma

Contacts and locations

Locations

  • Albemarle Eye Center

    Elizabeth City, North Carolina, 27909, United States

  • CORE, Inc.

    Shelby, North Carolina, 28150, United States

  • Central Florida Eye Associates

    Lakeland, Florida, 33805, United States

  • Central Florida Eye Specialists

    DeLand, Florida, 32720, United States

  • Coastal Research Associates

    Roswell, Georgia, 30076, United States

  • Coldwater Vision Research

    Coldwater, Mississippi, 38618, United States

  • East Coast Institute for Research, LLC

    Jacksonville, Florida, 32256, United States

  • Eye Doctors of Arizona

    Phoenix, Arizona, 85028, United States

  • Eye Research Foundation

    Newport Beach, California, 92663, United States

  • Glaucoma Specialists of South Florida

    Delray Beach, Florida, 33484, United States

  • Kannarr Eye Care LLC

    Pittsburg, Kansas, 66762, United States

  • Las Vegas Eye Institute

    Henderson, Nevada, 89052, United States

  • Lee Shettle Eye

    Largo, Florida, 33773, United States

  • Midwest Eye Center

    Cincinnati, Ohio, 45236, United States

  • North Bay Eye Associates

    Petaluma, California, 94954, United States

  • North Georgia Eye Associates

    Gainesville, Georgia, 30501, United States

  • NorthEast Eye Research Associates, LLC

    Westborough, Massachusetts, 01581, United States

  • Oculus Research, Inc.

    Garner, North Carolina, 27529, United States

  • Orange County Ophthalmology Medical Group

    Garden Grove, California, 92843, United States

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Rochester Ophthalmological Group

    Rochester, New York, 14618, United States

  • Sacramento Eye Consultants

    Sacramento, California, 95815, United States

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania, 16066, United States

  • Southern College of Optometry

    Memphis, Tennessee, 38104, United States

  • The Eye Institute of Utah

    Salt Lake City, Utah, 84107, United States

  • The Eye Institute of West Florida

    Largo, Florida, 33770, United States

  • Total Eye Care, PA

    Memphis, Tennessee, 38119, United States

  • Trinity Research Group

    Dothan, Alabama, 36301, United States

  • United Medical Research Institute

    Inglewood, California, 90301, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.